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Recent insights into the mechanisms by which
Mycobacterium tuberculosis, the etiologic agent
of human tuberculosis, is recognized by cytosolic
nucleotide sensors have opened new avenues for
rational vaccine design. The only licensed anti-tuber-
culosis vaccine,Mycobacterium bovis BCG, provides
limited protection. A feature of BCG is the partial dele-
tionof theESX-1 typeVII secretionsystem,whichgov-
ernsphagosomal rupture andcytosolic pattern recog-
nition, key intracellularphenotypes linked to increased
immunesignaling.Here, byheterologously expressing
the esx-1 region of Mycobacterium marinum in BCG,
we engineered a low-virulence, ESX-1-proficient, re-
combinant BCG (BCG::ESX-1Mmar) that induces the
cGas/STING/TBK1/IRF-3/type I interferon axis and
enhances AIM2 and NLRP3 inflammasome activity,
resulting in both higher proportions of CD8+ T cell ef-
fectors against mycobacterial antigens shared with
BCG and polyfunctional CD4+ Th1 cells specific to
ESX-1 antigens. Importantly, independent mouse
vaccination models show that BCG::ESX-1Mmar con-
fers superior protection relative to parental BCG
againstchallengeswithhighlyvirulentM.tuberculosis.INTRODUCTION
Tuberculosis (TB) is a chronic infectious disease caused by
Mycobacterium tuberculosis that continues to be among the
top five causes of death in 18 countries (GBD 2013 Mortality
and Causes of Death Collaborators, 2015). Increased prevention2752 Cell Reports 18, 2752–2765, March 14, 2017 ª 2017 The Autho
This is an open access article under the CC BY-NC-ND license (http://would be a tremendous asset in controlling the global epidemic,
as reflected byWorld HealthOrganization’s newEnd TBStrategy
(Uplekar et al., 2015). Rational design of an improved vaccine that
is able toprevent activediseasewouldbe themost effectivemea-
sure in TB control (Knight et al., 2014). Thus, numerous efforts are
beingundertaken todevelop improvedanti-TBvaccines, someof
which have recently entered clinical development (Fletcher et al.,
2016; Grode et al., 2013; Spertini et al., 2015).
The currently licensed anti-TB vaccine Mycobacterium bovis
BCG, also known as Bacille Calmette Gue´rin, confers insufficient
protection against pulmonary TB in adolescents and adults
(Kaufmann et al., 2015). The absence of a 9.5-kb genomic region
acrossall BCGstrains, termedRegionofDifference1 (RD1), is the
principal molecular determinant underlying BCG attenuation
(Hsu et al., 2003; Pym et al., 2002). RD1 harbors genes required
for theparadigm typeVII secretion (T7S) ESX-1, or ESAT-6 secre-
tion system that is dedicated to the export of proteins that play
key roles in host-pathogen interactions and pathogenic potential
(Gro¨schel et al., 2016). During infection of host phagocytes, a
functional ESX-1 secretion system and selected lipids (i.e.,
phthiocerol dimycocerosates) are required for communication
ofM. tuberculosiswith the host cytosol (Simeone et al., 2016; Au-
genstreich et al., 2017), with subsequent detection of bacterial
DNA by cytosolic sensors, and mitochondrial stress (Wiens and
Ernst, 2016). This process leads to a cascade of innate immune
signaling events (Collins et al., 2015; Wassermann et al., 2015;
Watson et al., 2015), including reinforced AIM-2 (Absence inMel-
anoma 2) and NLRP3 inflammasome activation, increased inter-
leukin-1b (IL-1b) and/or IL-18 secretion (Dorhoi et al., 2012; Kupz
et al., 2016; Wong and Jacobs, 2011) and activation of the cy-
clic GMP-AMP synthase (cGas)/Stimulator of Interferon Genes
(STING)/TANK-binding kinase 1 (TBK1)/IRF3 axis. The latter
signaling cascade results in the production of type I interferons
(IFNs) (Stanley et al., 2007). Apart from innate immune activation,
secreted ESX-1 effectors also induce specific host Th1 cellr(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Stable Genetic Complementation of BCG Pasteur Integrating the esx-1 Region of M. marinum
(A) Schematic representation of the integrating vector (Bange et al., 1999), the NheI cloning site, and the 38.7-kb insert fromM. marinumM containing the esx-1
locus. Amino acid sequence identities between gene products in the orthologous esx-1 loci of M. marinum and M. tuberculosis are depicted in percentages.
(B) PCR-based verification of the integration of the esx-1 locus into BCG::ESX-1Mmar, using several primers spanning the esx-1 locus ofM.marinum and negative
and positive DNA controls.
(C) Ethidium-bromid stained fragments of XhoI restriction digest of pRD1-Mmar, separated by agarose gel electrophoresis.
(legend continued on next page)
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responses with strong protective potential (Brodin et al., 2004,
2006). Early attempts to improve the protective efficacy of BCG
by heterologously expressing ESX-1 from M. tuberculosis, a
biosafety level (BSL) 3 organism, produced mixed results. Vac-
cine efficacy was improved (Pym et al., 2003), but as a side effect
virulence was increased (Pym et al., 2002), making this recombi-
nant BCG strain likely too virulent as to be used for vaccine appli-
cations. Thus, the rationale emerged to express the ESX-1 sys-
tems of related but less pathogenic mycobacteria in BCG.
M. tuberculosis H37Rv and M. marinum, a BSL2 aquatic myco-
bacterium that can infect fish or frogs and occasionally causes
skin infections in humans, share a substantial core genome,
with high amino acid sequence conservation, particularly across
the genes encoding the ESX-1 system (Figure 1A). Here, we en-
gineered a recombinant BCG candidate vaccine that harbored
the esx-1 locus ofM. marinum (BCG::ESX-1Mmar). We then inter-
rogated the biological and immunological consequences of this
heterologous ESX-1Mmar expression in the context of vaccina-
tion. Using different murine infection models, we identified previ-
ously undiscovered immunological features of recombinant BCG
linked to cytosolic pattern recognition andweprovide compelling
evidence of significantly improved protective vaccine efficacy.
RESULTS
Construction of the Recombinant BCG
ESX-1Mmar-Proficient Strain
An esx-1 locus-containing clone was selected from a Bacterial
Artificial Chromosome (BAC) library of M. marinum reference
strain M. This library was originally constructed to scaffold and
validate the whole-genome sequence assembly of this strain
(Stinear et al., 2008). The BAC clone was used as substrate for
sub-cloning a 38.7-kb-sized fragment into the integrating cos-
mid vector pYUB412 (Bange et al., 1999) (Figures 1A and 1B).
Sequence analysis revealed that the cloned fragment carried a
nucleotide deletion in the eccCb1 gene (6 C instead of 7 C in
the published genome sequence [Stinear et al., 2008] GenBank
CP000854 at position 6589,378-84) (Figure S1), causing a frame-
shift in EccCb1. Further analysis showed that the same eccCb1
nucleotide deletion was present in the genome of the M strain
(MPasteur), used for construction of the BAC library (Figure S1).
This finding likely explains the previously reported differences
in ESAT-6 secretion and virulence between the attenuated
M. marinum MVU variant and other M. marinum M variants
used in diverse laboratories (Abdallah et al., 2009; Hagedorn
et al., 2009; Ramakrishnan et al., 2000; Simeone et al., 2012),
as the M. marinum MVU also harbors this mutation. The frame-
shift in the cosmid was repaired using a phage lambda Red re-
combineering approach (Chaveroche et al., 2000). We then
transformed the ESX-1-repaired cosmid into BCG Pasteur
1173P2 (Figure 1C). Comparison of the in vitro growth character-(D) Demonstration of secretion of different ESX-1 substrates by BCG::ESX-1Mmar s
antigenic presentation of ESAT-6, EspC and CFP-10 by BM-DCs generated from
T cell hybridomas; NB11 (specific to ESAT-6:1-20, restricted by I-Ab), IF1 (specific
by I-Ak), respectively. In this assay, the efficacy of antigenic presentation, evalua
ESX-1 secreted substrate. The DE10 hybridoma (specific to Ag85A:241-260, re
results are representative at least of two independent experiments.
2754 Cell Reports 18, 2752–2765, March 14, 2017istics of the obtained recombinant BCG::ESX-1Mmar strain
showed that they were similar to other BCG strains (Figure S2A).
The Heterologous ESX-1 System Is Functional in the
BCG::ESX-1Mmar
The main secretedM. tuberculosis ESX-1 effectors ESAT-6 and
CFP-10 share very high amino acid sequence identity with their
M. marinum orthologs (Figure S2B), so we assessed the func-
tionality of the heterologous ESX-1Mmar secretion machinery
by using major histocompatibility complex (MHC)-II-restricted
T cell hybridomas specific to different ESX-1 effectors. In this
model, presentation of ESX-1 effectors is dependent on their
proper secretion (Frigui et al., 2008). BCG::ESX-1Mmar-infected
bone-marrow-derived dendritic cells (BM-DCs) presented
ESAT-6Mmar and CFP-10Mmar to specific T cell hybridomas
in a manner indistinguishable from BCG::ESX-1Mtb-infected
BM-DCs (Figure 1D). Similarly, EspC (Rv3615c), an ESX-1-
secretion-associated protein that forms secretion-needle-like
structures (Ates and Brosch, 2017; Lou et al., 2017), and is ex-
ported in a co-dependent way with ESAT-6 (MacGurn et al.,
2005), was efficiently presented by BM-DCs infected with either
BCG::ESX-1Mmar andBCG::ESX-1Mtb (Figure 1D). All tested BCG
strains induced the antigenic presentation of the control anti-
gen Ag85A, secreted by the Twin-Arginine Translocation (TAT)
pathway (Figure 1D). These data confirmed the functionality of
the heterologousM.marinum ESX-1 system in BCG::ESX-1Mmar,
including the successful interaction with the trans-acting
EspACD proteins of BCG that are encoded outside the cos-
mid-contained M. marinum fragment.
BCG::ESX-1Mmar Shows Reduced Virulence Compared
to BCG::ESX-1Mtb
We next compared in vivo growth in severe combined immuno-
deficient (SCID) mice of BCG::ESX-1Mmar with M. tuberculosis
H37Rv, BCG::ESX-1Mtb and parental BCG Pasteur. In this
model in which weight loss is an index of disease development,
BCG::ESX-1Mmar induced a weight-loss curve similar to BCG
Pasteur (Figures 2A and 2B). In contrast, mice infected with
M. tuberculosis H37Rv or BCG::ESX-1Mtb lost 20% of their
weight significantly earlier, indicating that BCG::ESX-1Mmar is
more attenuated than BCG::ESX-1Mtb (Pym et al., 2002, 2003).
BCG::ESX-1Mmar Modulates the Host Innate Immune
Response via Phagosomal Rupture
To determine further ESX-1Mmar-associated biological conse-
quences,wefirst confirmed thatBCG::ESX-1Mmar inducedpheno-
typic and functional maturation of DC in a similar manner as
control strains (BCG::pYUB, BCG::ESX-1Mtb and wild-type (WT)
M. tuberculosis H37Rv). This effect was evaluated by the upregu-
lation of the CD40, CD80, and CD86 co-stimulatory molecules,
modulation of MHC-I/II expression (Figure S3A), and productiontrain through antigenic presentation by infected phagocytes.MHC-II-restricted
C57BL/6 (H-2b) or C3H (H-2k) mice, infected in vitro by different BCG strains, to
to EspC:40-54, restricted by I-Ab) or XE12 (specific to CFP-10:11-25, restricted
ted by T cell activation and IL-2 production, is proportional to the amounts of
stricted by I-Ab) was used as a positive control. Error bars represent SD. The
Figure 2. Attenuated Virulence of BCG::ESX-1Mmar Strain, as Evalu-
ated in Immunocompromised Mice
(A and B) SCID mice (n = 10 per group) were infected intravenously (i.v.) with
1 3 106 colony-forming units (CFUs)/mouse of different recombinant BCG
strains in order to monitor the percentage of their weight change (A) and the
survival (B) compared to M. tuberculosis H37Rv (WT Mtb). Mice were killed
when reaching the humane endpoint, defined as the loss of >20% of body-
weight in accordance with ethics committee guidelines. The obtained median
survival times for groups of SCID mice were the following: Mtb WT 20 d;
BCG::ESX-1Mtb 28 days; BCG::ESX-1Mmar 53.5 days; BCG Pasteur 64 days.
Statistical analyses using the log-rank (Mantel-Cox) test performed with
GraphPad Prism showed that the differences in survival between groups of
animals infected with BCG::ESX-1Mmar and Mtb WT or BCG::ESX-1Mtb were
highly statistically significant (****p < 0.0001), whereas for BCG::ESX-1Mmar
versus BCG Pasteur no significant difference was obtained (p = 0.2136). In
contrast, median survival times for BCG::ESX-1Mtb versus BCG Pasteur were
highly statistically significant.of pro/anti-inflammatory cytokines and chemokines (Figure S3B).
As selected ESX-1-proficient mycobacteria such asM. marinum,
M. kansasii, orM. tuberculosis (Simeone et al., 2012; Stammet al.,
2003; Wang et al., 2015) have been shown to induce ESX-1-
mediated phagosome-to-cytosol communication, we explored
whether BCG::ESX-1Mmarwas able to inducephagosomal rupture
inhostphagocytes.Weusedaflow-cytometricfluorescence reso-
nance energy transfer (FRET) approach based on a green-to-blue
fluorescence shift following cleavage of cytosolic coumarin-ceph-
alosporin-fluorescein 4 (CCF4) by endogenous mycobacterialb-lactamase (Simeone et al., 2015). Analysis of infected human
THP-1 macrophages revealed that BCG::ESX-1Mmar induced a
solid blue shift, implying contact with the host cytosol, albeit
to a lesser degree compared to M. tuberculosis H37Rv and
BCG::ESX-1Mtb (Figure 3A). In contrast, the ESX-1-deficient nega-
tive control BCG strain did not induce a blue shift in the infected
cells (Figure 3A).
Infection of WT THP-1 macrophage-like cells with BCG::
ESX-1Mmar or control strains showed that BCG::ESX-1Mmar and
BCG::ESX-1Mtb both induced IFN-b production, although at a
lower level than WTM. tuberculosis. In comparison, IFN-b secre-
tionwas not detected in BCG::pYUBandM. tuberculosisDESX-1
(Figure 3B). Infection of THP-1 cells deficient in either cGAS or
STING, revealed that neither BCG nor M. tuberculosis (either
WT or recombinant) led to IFN-b release (Figure 3C). As a func-
tional control, we showed that cGAS or STING-deficient THP-1
cells releasedtumornecrosis factor-a (TNF-a)-likeWT(Figure3C).
These data support our contention that a type I IFN response by
ESX-1-proficient BCG strains depends on cytosolic exposure of
mycobacterial DNA to then associate with cGAS.
In parallel, we found that infection with BCG::ESX-1Mmar,
BCG::ESX-1Mtb or WT M. tuberculosis, significantly enhanced
release of active IL-1b, compared to BCG::pYUB and
M. tuberculosisDESX-1 (Figure 3B). These data are in agreement
with earlier studies, which revealed that the release of active
IL-1b is partially dependent on the interaction of mycobacterial
DNA with AIM2 (Saiga et al., 2015).
Since ESX-1-dependent activation of STING has been re-
ported to increase autophagy (Watson et al., 2012), we tested
whether the BCG::ESX-1Mmar or BCG::ESX-1Mtb increased the
presence of the cytosolic autophagy effector microtubule-asso-
ciated protein 1A/1B-light chain 3 (LC3)-II. Using a flow-cytome-
try-based assay, we observed increased LC3-II accumulation
in THP-1 cells infected with ESX-1-proficient recombinant
BCGs relative to BCG::pYUB-infected cells (Figure S4A), without
notable differences in cell mortality (Figure S4B). However, the
observed differences between BCGWT and recombinant strains
remained relatively small, in concordance with previous studies
using western blotting or confocal microscopy (Romagnoli
et al., 2012; Watson et al., 2012) (Figure S4A).
BCG::ESX-1Mmar Induces Potent Polyfunctional Th1 Cell
Responses against ESX-1-Secreted Antigens
Protection against TB largely depends on the host’s ability to
generate potent Th1 cell responses against mycobacterial
protective antigens (Majlessi et al., 2015). C57BL/6 (H-2b) or
C3H (H-2k) mice, immunized subcutaneously (s.c.) with BCG::
ESX-1Mmar, mounted IFN-g T cell responses against esx-1-
encoded ESAT-6 and CFP-10 antigens as well as ESX-1-secre-
tion-associated EspC (Figures S5). These responseswere similar
to those detected in the BCG::ESX-1Mtb- or WTM. tuberculosis-
immunized groups. BCG::ESX-1Mmar-immunized mice also dis-
played IFN-g T cell responses against non-ESX-1-associated an-
tigens shared with BCG that were comparable to those induced
by the BCG::pYUB control, as exemplified by Ag85A-, PE19-,
or PPE25-specific IFN-g release (Figure S5A).
In-depthcharacterizationof the functional Th1subsetsby intra-
cellular cytokine staining (ICS) (Figures 4A, S6, and S7) showedCell Reports 18, 2752–2765, March 14, 2017 2755
Figure 3. Dynamic Effects of Functional ESX-1 Secretion System of BCG::ESX-1Mmar on the Host Innate Immune Responses
(A) Gating strategy and results of phagosomal rupture assay in WT THP-1 human macrophages, infected with different recombinant BCG strains, as detected at
day 3 post-infection by CCF-4 FRET-based cytometry, compared to controls (Sayes et al., 2016).
(B and C) ELISA-based quantification of IFN-b and IL-1b (B), or IFN-b and TNF-a (C) contents in the culture supernatants of the infectedWT or mutant THP-1 cells
at 24 hr post-infection. The results are representative of two independent experiments. NS, not significant, ** or ***, statistically significant, as determined by one-
way ANOVA test with Tukey’s correction, with p < 0.005 or p < 0.001, respectively. Error bars indicate SD levels.that BCG::ESX-1Mmar, BCG::ESX-1Mtb, as well as BCG::pYUB, all
induced comparable percentages of Th1 cytokine-producing
cells and similar compositions in single-, double-, and triple-Th1
cytokine producing cells, specific to the antigens present in
BCG, i.e., Ag85A (Figure 4B) and PE19 or PPE25 (Figure S7A).
In addition, BCG::ESX-1Mmar andBCG::ESX-1Mtb induced similar
ESAT-6- or EspC-specific Th1 responses (Figure 4B). Indeed, the
total percentage of Th1 cytokine-producing cells per mouse2756 Cell Reports 18, 2752–2765, March 14, 2017against these antigens was comparable among the mice immu-
nized with the two ESX-1-proficient recombinant BCG strains
(Figure S7). The responses were dominated by IL-2+ TNF-a+
and TNF-a+ IFN-g+ double-positive and IL-2+ TNF-a+ IFN-g+
triple-positive CD4+ T cells. Furthermore, the amount of Th1
cytokines produced by ESAT-6 specific CD4+ T cell subsets in
response to BCG::ESX-1Mmar and BCG::ESX-1Mtb were compa-
rable (Figure 4C).
Figure 4. Dissection of Th1 Cell Responses Induced by BCG::ESX-1Mmar Immunization
(A) Gating strategy adopted to detect different functional subsets of specific Th1 effectors in the spleen of BCG::ESX-1Mmar-immunized C57BL/6 mice using ICS.
Cytometric plots represent 5% contours, representative of three mice per group. Shown are cultures of splenocytes stimulated by ESAT-6:1-20.
(B) Percentages of antigen-specific Th1 cytokine producing T cells compared to total CD4+ T splenocytes (left) and composition of Th1 cytokine-producing
functional CD4+ T cells, specific to different mycobacterial antigens, at 28 days post-immunization. Total splenocytes from each group were stimulated
in vitro with 10 mg/mL of different synthetic peptides containing I-Ab-restricted immunodominant epitopes, prior to ICS, in order to determine frequencies of
(legend continued on next page)
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BCG::ESX-1Mmar Boosts Initiation of Anti-Mycobacterial
Host CD8+ T Cell Immunity
Independent lines of evidence point to a major role of CD8+
T cells in anti-mycobacterial protection (Behar, 2013; Ryan
et al., 2009). To evaluate the impact of BCG complementation
with ESX-1, we immunized C3H (H-2k) mice that specifically
recognize a MHC-I-restricted CFP-10:32-39 epitope (Kamath
et al., 2004) and found that the mice mounted CD8+ T cell re-
sponses against CFP-10, as detected by IFN-g production
subsequent to stimulation of splenocytes with the peptide
(Figure 5A). In addition, higher percentages of TNF-a+ IFN-g+
bi-functional CD8+ T cells specific to Ag85A:144-152 (Denis
et al., 1998), TB10.4:20-28 (Majlessi et al., 2003), or PPE26:
44-52- (Sayes et al., 2012) MHC-I-restricted epitope were de-
tected in the spleen of BCG::ESX-1Mmar- or BCG::ESX-1Mtb-
immunized BALB/c (H-2d) mice, relative to their BCG-immunized
counterparts (Figure 5B). The increase in CD8+ T cell responses
against non-ESX-1-secreted antigens upon immunization with
ESX-1-proficient BCGs supports the notion that ESX-1-medi-
ated phagosomal rupture facilitates cross-presentation of myco-
bacterial antigens either due to type I IFN production (Le Bon
et al., 2003) or by enhanced access of antigens to the cytosolic
presentation machinery (van der Wel et al., 2007). The potentially
increased persistence of ESX-1-proficient BCGs in the vacci-
nated host may also contribute to sustained availability of myco-
bacterial antigens required for the initiation of robust CD8+ T cell
effectors (Woodworth et al., 2008).
BCG::ESX-1Mmar Protects Mice from TB Better than
Standard BCG Vaccines
To assess the protective efficacy of the BCG::ESX-1Mmar
as a potential vaccine candidate, we immunized s.c. groups
of C57BL/6 mice (n = 5 per group) with the different BCG strains.
After 4 weeks, mice were challenged withM. tuberculosisH37Rv
via the aerosol route andmycobacterial loadswere determined in
lungs and spleen 4 weeks later (Figure 6A). Both BCG ESX-1-
proficient strains were superior to BCG Danish 1331, the model
control BCG strain used in TB vaccine research, or BCG::pYUB
in protecting against anM. tuberculosis H37Rv challenge both in
the lungs and in spleen (Figures 6B and 6C) in this model. These
data suggest that BCG::ESX-1Mmar and BCG::ESX-1Mtb show
similar protective efficacies that are, in turn, superior to the
parental BCG strains.
To further explore its protectiveperformance,BCG::ESX-1Mmar
was tested in an independent preclinical vaccine trial within the
framework of the TBVAC2020 consortium, where potential TB
vaccine candidates are compared head-to-head relative to
BCG Danish 1331 (Figure 7A). BCG::ESX-1Mmar showed signifi-
cantly enhanced protection against a challenge with the highly
virulent M. tuberculosis strain HN878 (Beijing family) (Figure 7B)
andM. tuberculosisstrainM2 fromtheHarleemfamily (Figure7C),
as evidencedbygreatly reducedmycobacterial loads in the lungssingle-, double-, or triple-positive CD4+ cells producing IL-2, TNF-a, and/or IFN
correction.
(C) The geometric mean fluorescence intensities (MFIs), proportional to the int
functional Th1 subsets, as determined in the spleen of mice immunized with BCG:
and S7.
2758 Cell Reports 18, 2752–2765, March 14, 2017and spleen, as well as decreased proportions of inflamed lung
tissue (Figure 7D).
DISCUSSION
With millions of doses delivered across generations of humans
around the world, BCG is perhaps the most well-known example
of a live, attenuated vaccine and is still widely used today as
no higher-performing alternatives have been licensed to date.
Developed in the 1920s by Calmette and Gue´rin after long-
term in vitro passaging of a virulentMycobacterium bovis isolate
that became irreversibly attenuated, vaccination with BCG of an
estimated 3 billion individuals confirmed that BCG was safe in
the immunocompetent host (Fine et al., 1999). Besides BCG,
the other human anti-TB vaccine used at a larger scale is the
vole-bacillus Mycobacterium microti. Different attenuated vari-
ants were successfully used to vaccinate 10,000 adolescents
in the UK (Hart and Sutherland, 1977) and half a million babies
in the former Czechoslovakia (Sula and Radkovsky´, 1976) in
the 1960s.
However, reflection on the history of almost 100 years of hu-
man anti-TB vaccination shows that despite undeniable benefi-
cial effects conferred to small children, vaccination with BCG or
M. microti has been insufficient to prevent the current global re-
emergence of TB. Interestingly, BCG andM. microti strains have
one major genetic feature in common. They have independently
deleted portions of the region of difference 1 (RD1) (Mahairas
et al., 1996; Brodin et al., 2002), which in M. tuberculosis and
many other mycobacteria encodes the ESX-1 type VII secretion
system (Abdallah et al., 2007; Bottai et al., 2016; Gro¨schel et al.,
2016). The biological basis for key ESX-1-mediated effects are
primarily linked to the ESX-1-dependent induction of phago-
some-cytosol communication (Simeone et al., 2012, 2015; van
der Wel et al., 2007; Conrad et al., 2017). Indeed, mycobacterial
cytosolic contact triggers a cascade of cellular signaling events
that are of upmost importance for innate and adaptive im-
mune responses. ESX-1-deficient BCG and M. microti vaccine
strains are unable to initiate these responses (Gro¨schel et al.,
2016; Majlessi and Brosch, 2015; Majlessi et al., 2015).
We reasoned that influencing phagosome biology through
ESX-1 secretion might enhance the protective ability of BCG,
and we wanted to uncouple the beneficial immunological ESX-
1-mediated effects from the gain-of-virulence linked to the
insertion of genes from a BSL3 organism into BCG. We thus
heterologously expressed in BCG the ESX-1 from M. marinum,
a mycobacterium that shares with BCG the BSL2 classifi-
cation. Successful integration of the M. marinum ESX-1 locus
was confirmed by PCR and use of a panel of ESX-1 antigen-
specific T cell hybridomas. Interestingly, we detected lower
antigenic presentation of CFP-10 by dendritic cells infected
with BCG::ESX-1Mmar compared to BCG::ESX-1Mtb, which
might reflect a lower CFP-10 antigen availability due to the-g. NS, not significant as determined by one-way ANOVA test with Tukey’s
racellular amounts of IL-2, TNF-a, or IFN-g, in each of the ESAT-6-specific
:ESX-1Mmar or BCG::ESX-1Mtb. Additional information is provided in Figures S6
Figure 5. Enhanced Induction of Key CD8+ T Cell Effectors by BCG::ESX-1Mmar in Immunocompetent Mice
(A) T cell IFN-g responses of C3H (H-2k) mice (n = 3 per group) immunized s.c. with 13 106 CFUs/mouse of different BCG strains, as assessed at 4 weeks post-
immunization. Pool of total splenocytes of the immunized mice were stimulated in vitro with synthetic MHC-I-restricted CFP-10-derived peptides during 72 hr.
Error bars represent SD.
(B) Detection of TNF-a- and/or IFN-g-producing CD3+ CD4- CD8+ T splenocytes by ICS applied on total splenocytes of BALB/c (H-2d) mice (n = 3 per group),
immunized s.c. with 1 3 106 CFUs/mouse of different BCG strains. At 5 weeks post-immunization, splenocytes were stimulated in vitro with MHC-I H-2Kd-
restricted epitopes from Ag85A, TB10.4, PPE26, or the LCMV-NP:118-126 as a negative control peptide. In parallel, stimulated cells were stained with control
immunoglobulin (Ig) isotypes. Cytometric plots represent 5% contours with outliers, representative of three mice per group. The results are representative of two
independent experiments.
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Figure 6. Improved Protection Potential of
BCG::ESX-1Mmar Strain Significantly En-
hances Protective Capacity against an
M. tuberculosis H37Rv Challenge in Mice
(A) Immunization protocol of mice adopted in order
to evaluate protective capacity of different BCG
strains.
(B and C) C57BL/6 mice (n = 5 per group) were
left unimmunized or vaccinated s.c. with 1 3 106
CFUs/mouse of BCG Pasteur::pYUB, BCG
Danish, BCG::ESX-1Mtb or BCG::ESX-1Mmar strain
withz150 CFUs/mouse ofM. tuberculosis H37Rv
strain via aerosol route, as determined by CFU
counting in the lungs day 1 post-infection. The
mycobacterial loads in the lungs (B) and spleen
(C) of individual mice were determined. NS, not
significant, *, **, ***, ****, statistically significant, as
determined by one-way ANOVA test with Tukey’s
correction, with p < 0.05, p < 0.005, p < 0.001, or
p < 0.0001, respectively. Note that for these ex-
periments a H37Rv M. tuberculosis strain was
used that was passaged in the past in mice to
maintain high virulence, and that the inoculum for
the aerosol challenge was prepared from expo-
nentially growing cultures.heterologous expression of M. marinum proteins that need to
cooperate for secretion with proteins from BCG.
The introduction of the ESX-1Mmar region intoBCG resulted in a
minor, non-significant increase in virulence relative to parental
BCGPasteur andwas greatly reduced compared to the virulence
of BCG::ESX-1Mtb. As the magnitude of phagosomal rupture by
BCG::ESX-1Mmar and BCG::ESX-1Mtb was comparable, it sug-
gests that phagosome escape is not the only determining fac-
tor that explains the virulence differences observed between
ESX-1-proficient and ESX-1-deficient mycobacteria. Alterna-
tively, the heterologous expression of a large DNA fragment
from a more distantly related species with different host speci-
ficity, i.e., M. marinum, in BCG might reduce the in vivo fitness
of the recombinant BCG::ESX-1Mmar, although we observed
similar in vitro growth characteristics to standard BCG.
We next evaluated the immunological repercussions of the
ESX-1-introduction into BCG by analyzing innate immune re-
sponses, particularly in light of the most recent literature. IL-1b
is protective in the context ofM. tuberculosis infection (Fremond
et al., 2007), and its catalytic cleavage is mediated by the NLRP3
inflammasome/caspase-1 pathway (Muruve et al., 2008). We
showed that ESX-1-proficient BCGs mount a higher IL-1b
response suggesting that cytosolic access of mycobacterial
compounds promotes activation of the inflammasome. In addi-
tion to induction of IL-1 b, recent evidence points to a role for
ESX-1-mediated cytosolic contact in NLRP3-inflammasome-
mediated secretion of IL-18 by infected CD11c+ immune cells
(Kupz et al., 2016). This leads to non-cognate production of
IFN-g by M. tuberculosis-antigen-independent memory CD8+
T cells and NK cells. Such IL-18-dependent and rapid IFN-g
responses are not induced by current anti-TB vaccines (Gen-
genbacher et al., 2016; Kupz et al., 2016). In this context, the
rationale is strengthened for leveraging ESX-1 function as an
important additional element in the design of third-generation
vaccines and host-directed therapy against TB.2760 Cell Reports 18, 2752–2765, March 14, 2017Byacquiring cytosolic access,mycobacterialmolecular finger-
prints, such as extracellular DNA, can also be sensed by germ-
line-encoded pattern recognition receptors in host cell such
as AIM2 (Hornung et al., 2009; Saiga et al., 2015) or cGAS (Collins
et al., 2015; Wassermann et al., 2015; Watson et al., 2015).
We observed that the BCG::ESX-1 strains induced IFN-b medi-
ated by the cGAS/STING pathway in human macrophages.
We acknowledge that the role of type I IFNs in the context of
M. tuberculosis infection is somewhat conflicted (McNab et al.,
2015). Studies in humans (Berry et al., 2010) and in animalmodels
report a detrimental role of type I IFNs during M. tuberculosis
infection (Manca et al., 2005; Ordway et al., 2007; Stanley et al.,
2007). A possible explanation is that IFN-a/b undermine inflam-
masome activation and associated host protective cytokines
such as IL-1b (Guarda et al., 2011). However, this pro-bacterial
role of type I IFNs during infection with M. tuberculosis could
turn out to bepro-host during vaccination.While type I IFNsnega-
tively regulate active IL-1b secretion duringM. tuberculosis infec-
tion (Novikov et al., 2011), we observed both increased IL-1b and
IFN-b production induced by the ESX-1-proficient BCG vaccine
candidates. Therefore, if an activated cGas/STING/TBK1/IFR3/
type I IFN pathway contributes to the persistence of attenuated
vaccine strains and the activation of non-infected neighboring
cells (Ablasser et al., 2013), this effect might favorably increase
the spatial and temporal interplay between the vaccine and the
host immune system, ultimately contributing to improved vaccine
efficacy.
Apart from the prompt innate immune response, the late
adaptive immune system plays a key role in anti-mycobacterial
immunity (Orme et al., 2015). We found that the BCG::
ESX-1Mmar induces a potent Th1 cell response against strong
immunogens exported by ESX-1, which enlarges the antigenic
repertoire compared to the currently used BCG vaccine, and
thus represents a desirable feature in the light of the incomplete
protection conferred by BCG. The presence of polyfunctional
Figure 7. Improved Protection Potential of BCG::ESX-1Mmar Strain Relative to Standard BCG Strains in Mice against a Challenge with
Hypervirulent M. tuberculosis Strains HN878 and M2
(A) Immunization protocol with different BCG strains.
(B and C) Bacterial loads in the lungs and spleens 26 weeks post-immunization and 16 weeks after aerosol challenge with theM. tuberculosis HN878 (B) or M2
(C) strains.Mice were challengedwith theM. tuberculosisHN878 strain (approximately 200CFUs/mouse) orM2 strain (approximately 50–60CFUs/mouse) via the
aerosol route. TheCFUs in the lungs and spleens of each groupwere analyzed by culturing lung and spleen homogenates and enumerating the bacteria. Note that
CFU data shown correspond to counts that were obtained from the left-superior lobes of the lungs. The data are presented as the median ± interquartile range
(IQR) log10 CFUs/organ (n = 6), and the levels of significance for comparisons between samples were determined by a one-way ANOVA, followed by Dunnett’s
multiple comparison test.
(legend continued on next page)
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Th1 cytokine-producing cells against ESX-1-secreted antigens
upon vaccination with the recombinant BCGs adds another
convincing feature of the broadened T cell specificities. Apart
from CD4+ T cells, we detected improved CD8+ T cell responses
by analyzing functional CD8+ T cells. This strong adaptive im-
mune response could be partly explained by a bridging function
of activated IFN-b between innate and adaptive immunity, as
has been described for type I IFNs (Le Bon et al., 2003). Impor-
tantly, in addition to type I IFNs IL-1b and inflammasome activa-
tion also play roles in regulating the differentiation and function
of CD8+ T cells during M. tuberculosis infection (Booty et al.,
2016). CD8+ T cell effectors are primed through increased in-
flammasome signaling (IL-1b), in concert with the upregulation
of chemo-attractants CCL2, CCL5, and CXCL10, of which we
detected elevated levels (Figure S3B) (Le Bon et al., 2003; Sa-
goo et al., 2016). These data support a model where ESX-1-
mediated cytosolic access assists presentation to and activa-
tion of the cytosolic presentation machinery through induction
of type I IFNs (Le Bon et al., 2003) and potentially increased bac-
terial persistence (Woodworth et al., 2008).
The hypothesis that ESX-1-mediated cytosolic access im-
proves the performance of recombinant BCG through enhanced
innate immune signaling and enlarged antigenic repertoire is
supported by our results from the mouse models where BCG::
ESX-1Mmar showed superior protective efficacy compared to
parental BCG. These results are in accord with those obtained
using an attenuatedM. tuberculosis strain that lacks the charac-
teristic esx-5-associated pe/ppe genes, but harbors all other
components of the ESX-5 system, aswell as an intact ESX-1 sys-
tem (Sayes et al., 2012). Like BCG::ESX-1Mmar, this strain named
MtbDppe25-pe19 is able to induce innate immune responses
linked to cytosolic pattern recognition and shows significantly
improved protection against an M. tuberculosis challenge in a
mouse infectionmodel (Sayes et al., 2016). These results suggest
that, despite the different genetic background and the different
origin of theESX-1 system,ESX-1-mediated functions are essen-
tial for increasing protection levels above those provided by
vaccination with standard BCG strains.
In conclusion, the heterologous expression of anM. marinum-
derived ESX-1 system in BCG yielded a recombinant vaccine
candidate with relatively low virulence levels in SCIDmice, which
are comparable with those of other BCG strains (Zhang et al.,
2016), and a capacity to induce selected innate and adaptive
immune responses that depend on phagosome-cytosol commu-
nication in the host phagocyte. Such responses are not induced
by first-generation anti-TB vaccines such as BCG or M. microti
and might as well not be induced by the second-generation
anti-TB vaccine candidates that have recently entered clinical
development (Kupz et al., 2016). Given that 90%–95% of
M. tuberculosis exposed individuals do not develop active TB
disease during their lifetime, host immune effectors are largely
capable of inducing protective immunity (Ottenhoff and Kauf-(D) Lung samples collected for histopathology were preserved overnight in 10%
sections, and stained with H&E. The superior lobes of the right lung were stained w
lungs was evaluated using ImageJ software (NIH). Percentages of the inflamed
maximum values) (n = 6), and a one-way ANOVA followed by Dunnett’s test was
2762 Cell Reports 18, 2752–2765, March 14, 2017mann, 2012). We propose that a virulence-attenuated, ESX-1-
proficient BCG vaccine might be best able to mimic the natural
route of infection and induce the ‘‘correct’’ phagosomal biology,
leading to protective immunity at the same points of host-path-
ogen contact as M. tuberculosis. We argue that this important
biological feature should not be left out from the rational design
of third-generation vaccines, giving BCG::ESX-1Mmar a clear
potential to better control TB.
EXPERIMENTAL PROCEDURES
Mycobacterial Strains and Preparation of Recombinant Strains
Mycobacterial strains included theM. tuberculosis strains H37Rv (stocks held
at Institut Pasteur, Paris), HN878 and M2 (ITRC, Changwon), as well as the
BCG strains Pasteur 1173P2 and Danish 1331. Recombinant strains were ob-
tained by transformation with the pRD1-2F9 cosmid (Pym et al., 2002) and the
pESX-1Mmar cosmid described in detail in the Supplemental Information.
Antigen-Presenting Assay
Several MHC-II-restricted T cell hybridomas specific to mycobacterial anti-
gens were used in order to detect the secretion by mycobacteria, which leads
to the antigenic presentation by the infected BM-DCs of different ESX-1 sub-
strates, as described in detail in the Supplemental Information.
ELISA and Multiplex Cytokine and Chemokine Assays and FRET
Assays
Levels of various cytokines and chemokines in BM-DC culture supernatants
were determined by multiple ProcartaPlex (Affymetrix) kit assays and a Lumi-
nex X-100 Reader (Supplemental Information). For FRET analyses a recently
described protocol (Simeone et al., 2015) was used with THP-1 cells to detect
fluorescence emission changes from green (535 nm) to blue (447 nm) induced
by b-lactamase-mediated cleavage of coumarin-cephalosporin-fluorescein
(CCF-4) (Supplemental Information).
Immunogenicity and T Cell Assay and T Cell Intracellular Th1
Cytokine Assay
For immunological studies splenocytes from immunized C3H and C57BL/6
mice (Janvier) were cultured in 24- or 96-well plates in the presence of various
mycobacterial antigens, followed by ELISA-mediated quantification of IFN-g
and/or flow-cytometric analysis (described in detail in the Supplemental
Information).
In Vivo Experiments
Studies in immunocompetent and immunodeficient mice were performed ac-
cording to European and French guidelines (Directive 86/609/CEE and Decree
87–848 of 19October 1987) after approval by the Institut Pasteur Safety, Animal
Care and Use Committee (Protocol 11.245) and local ethical committees
(CETEA 2012–0005 and CETEA 2013–0036). In addition, independent vaccine
efficacy studies involvingM. tuberculosis HN878 and M2 challenges were per-
formed in accordancewithKoreanFoodandDrugAdministration (KFDA) guide-
lines and approved by the Ethics Committee and Institutional Animal Care and
UseCommittee (PermitNumber: 2015-0274) of theLaboratoryAnimalResearch
Center at Yonsei University College of Medicine (Seoul, Korea). More details on
these experiments are described in the Supplemental Information.
Statistical Analyses
For statistical analyses, GraphPad Prism software (GraphPad) was used as
described in detail in the Supplemental Information.normal buffered formalin, embedded with paraffin, sliced into 4- to 5-mm-thick
ith H&E to assess the severity of inflammation. The level of inflammation in the
areas are presented as whisker boxplots (whiskers represent minimum and
used to determine the significance of the findings.
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